[Table_Page] 中报点评|医疗器械 证券研究报告 [Table_Title] 澳华内镜（688212.SH） 公司业绩符合预期，加速海外市场产品准入 [Table_Summary] 核心观点： 公司业绩符合预期。根据公司 24 年半年报，24 年上半年，公司营收 3.54 亿元（YOY+22.29%）；归母净利润 0.06 亿元（YOY-85.13%）， 系公司的限制性股票激励计划和人力的持续投入增加；毛利率 71.46% （YOY-4.82pp），主要系公司成本随营收增加而增加。根据 wind，公 司 24 年 2 季度实现收入 1.84 亿元（YOY+12.61%）；归母净利润 0.03 亿元，环比增速 5.17%。 公司费率整体略增。根据 wind，公司 24 年上半年，销售费用率 34.69% （YOY+0.52pp），主要系职工薪酬及差旅费等费用增长；管理费用率 16.6%（YOY+2.69pp），主要系股份支付差旅费等费用增加；研发费用 率 24.7%（YOY+0.62pp），主要系职工薪酬及差旅费等费用增长。 公司新产品陆续迭代，加速海外市场产品准入。根据公司 24 年半年 报，24 ...

[Table_Page] 中报点评|电池 证券研究报告 [Table_Title] 亿纬锂能（300014.SZ） 储能电池出货增速陡峭，消费板块稼动率企稳回升 [Table_Summary] 核心观点： ⚫ 减值造成扰动，业绩整体符合预期。公司发布 2024 年半年报。2024 年 上半年实现营收 216.59 亿元，同比-5.73%；归母净利润 21.37 亿元， 同比-0.64%；扣非归母净利润 14.99 亿元，同比+19.32%。2024 年二 季度分别实现营收/归母净利润/扣非归母净利润 123.42/10.72/7.98 亿 元，同比分别+4.68%、+5.97%、+23.76%，环比分别+32.46%、+0.55%、 +13.77%；2024 年二季度减值计提合计约 0.94 亿元，其中信用减值损 失约 6360 万元，主要系应收账款的坏账准备计提。 ⚫ 储能电池出货增速陡峭，消费板块稼动率企稳回升。据公司财报，2024 年上半年公司动力业务营收 89.94 亿元，同比-25.79%，综合毛利率 11.45%，出货量 13.54GWh，同比+7.03%；储能业务营收 77.74 亿元， 同比+ ...

[Table_Title] 阳光电源（300274.SZ） 业绩超预期，全球储能影响力持续提升 [Table_Summary] 核心观点： 公司发布 2024 年半年报，业绩超预期。24 年上半年公司实现营收 310.20 亿元，同比+8.38%；毛利率 32.42%，同比+3.0pct，主要系公 司品牌溢价、产品创新及项目管理能力的提高；归母净利润 49.59 亿 元，同比+13.89%；财务费用 1.88 亿元，同比增长 4.97 亿元，主要系 汇兑损失金额大幅增加。24Q2 实现营收 184.06 亿元，同比+14.74%， 环比+45.92%；归母净利润 28.63 亿元，同比+0.57%，环比+36.56%。 逆变器业务经营稳健，微逆新品开拓欧洲户用市场。根据公司中报， 24 年上半年光伏逆变器业务出货 65GW，实现营收 130.93 亿元，同 比+12.63%，占总营收 42.21%，毛利率稳定在 38%左右。公司大力推 进全球化品牌战略，加码布局欧洲、美洲、澳洲、中国渠道市场，全球 服务网点增长至 490+。公司重磅发布微逆系列及家庭智慧能源管理器 iHomeManager，方便适应欧洲及全球 ...

[Table_Page] 中报点评|家用电器 证券研究报告 [Table_Title] 老板电器（002508.SZ） Q2 业绩受地产拖累，中期分红回报股东 [Table_Summary] 核心观点： ⚫ 老板电器发布 2024 年中报。24H1 营业收入 47.3 亿元（YoY-4.2%）； 归母净利润 7.6 亿元（YoY-8.5%）。毛利率 48.9%（YoY-3.1pct），归 母净利率 16.1%（YoY-0.8pct）。24Q2 单季收入 24.9 亿元（YoY-9.6%）； 归母净利润 3.6 亿元（YoY-18.2%）。 ⚫ 24H1 厨电行业受地产拖累整体承压，老板电器龙头地位稳固。行业 方面，根据公司中报引用的奥维数据，24H1 住宅竣工面积 19259 万 平方米，同比下降 21.7%，导致厨电行业新增需求明显下滑。虽然行 业总体承压，但老板电器市场份额依然稳固。根据奥维线下报告显示， 老板品牌吸油烟机零售额、零售量市场占有率为 31.9%、26.1%；根 据奥维线上报告显示，老板品牌厨电套餐零售额、零售量市场占有率 为 27.0%、20.9%；均位于行业第一。 ⚫ 盈利能力整体承压， ...

[Table_Page] 投资策略周报|机械设备 [Table_Title] 机械设备行业周报 美联储发出降息信号，外需有望迎来改善 [Table_Summary] 核心观点： 证券研究报告 [Table_Grade] 行业评级 买入 前次评级 买入 报告日期 2024-08-25 ⚫ 鲍威尔表示美联储降息时机已到。根据中新社，美国联邦储备委员会 主席鲍威尔 23 日在怀俄明州举行的杰克逊霍尔全球央行年度经济政 策研讨会上表示，美联储降息时机已到。鲍威尔在讲话中称，高通胀是 一个全球现象，反映了人们的共同经历。美联储毫不畏惧地履行职责， 其行动表明了恢复价格稳定的决心。自 2023 年 7 月以来，美联储一直 将联邦基金利率维持在限制水平。目前，通胀的上行风险已经减弱。鲍 威尔说，政策调整的时机已经到来，政策方向已经明确。降息的时间和 节奏将取决于即将发布的数据、不断变化的前景和风险平衡情况。 ⚫ 市场表现分析：本周（8 月 19 日-8 月 23 日）机械行业指数（中信） 下跌 2.70%，沪深 300 指数下跌 0.55%，创业板指下跌 2.80%。 ⚫ 机械动态变化：广义货币增长 6.3%，前七个月人民 ...

Xml [Table_Page] 跟踪分析|房地产 证券研究报告 [Table_Title] 房地产及物管行业 24 年第 34 周周报 住建工作聚焦新模式&保交房，二手网签成交止跌 [Table_Summary] 核心观点： ⚫ 本周政策情况：多维度推进发展新模式，融资协调机制助力保交房。 中央政策方面，本周国新办"推动高质量发展"系列新闻发布会陆续 召开，8 月 21 日金融监管总局强调完善融资协调机制以更好支持保交 房工作，8 月 23 日住建部主要围绕新模式以及保交房展开。地方政策 方面，本周厦门出台购房落户政策，长沙将住房认定标准缩小为所在 区，长沙、兰州等地积极推动收储，上海拟出台房屋体检、保险、养 老金三项制度，金山区发放首张房票。 ⚫ 本周基本面情况：推盘中枢下行，二手房网签成交止跌。据 Wind 及 克尔瑞，本周 51 城新房成交面积 374.4 万方，环比上升 6.3%，同比 下降 13.2%，新房成交热度略低于去年同期，当前新房成交热度低位 维稳。二手房方面，本周 13 城网签口径成交 149.7 万方，环比下降 0.4%，同比上升 14.2%，74 城认购口径日均成交 1785 套，环 ...

[Table_Page] 深度分析|环保 证券研究报告 [Table_Title] 固废行业巡礼（一） 特许经营权到期、国补退坡问题解答 [Table_Summary] 核心观点： ⚫ 引言：2024 年以来固废公司因其民生属性、盈利稳健、自由现金流大 幅改善等特点而备受市场关注，光大环境、瀚蓝环境、三峰环境等 2024 年至今涨幅分别为 48%、26%、21%，显著跑赢沪深 300、上证等行 业指数。我们推出"固废行业巡礼"系列报告，旨在对市场关心的重点 问题做出研究及解答，本篇"系列一"主要聚焦"特许经营权到期"及 "国补退坡"两个问题。 ⚫ 特许经营权到期问题：早期项目仅占比 5%以内，政策&实践案例均提 供了延期至 40 年的可能。固废项目大多采用特许经营权模式，项目期 限大多为 25~30 年，市场普遍担心到期后项目会移交给政府因而影响 上市公司的资产规模、利润体量。我们梳理了固废上市公司在运产能情 况，2010 年及以前投运的项目占公司总在运产能的比重约为 5%（千 吨左右），假设 25 年的经营期限，即 2035 年前项目到期的影响有限。 从政策指引来看，2024 年特许经营权新规发布，政策指引 ...

Investment Rating - The report maintains a "Buy" rating for the company [4]. Core Views - The company reported a positive growth in revenue, PPOP, and net profit attributable to shareholders for the first half of 2024, with year-on-year increases of 1.8%, 3.7%, and 0.9% respectively. Although there was a slight decline in growth rates compared to the first quarter of 2024, the overall performance remains stable [2][3]. - Key highlights include a significant improvement in deposit costs, with a net interest margin of 1.86% and a reduction in deposit cost rate by 18 basis points compared to the full year of 2023. The company also experienced steady asset growth, with total assets increasing by 4.6% year-on-year [2][3]. - The report indicates that the company's internal capital growth rate exceeds the growth rate of risk-weighted assets, suggesting sustainability in dividend payouts and high dividend value [2][3]. Summary by Relevant Sections Financial Performance - For the first half of 2024, the company achieved a revenue growth of 1.8%, PPOP growth of 3.7%, and a net profit growth of 0.9% compared to the previous year. The growth rates for revenue and PPOP showed a decline of 2.4 percentage points and 3.5 percentage points respectively from the first quarter of 2024, while net profit growth turned positive with an increase of 4.0 percentage points [2][3][11]. - The net interest margin for the first half of 2024 was reported at 1.86%, with a marginal decline of only 1 basis point from the previous quarter, indicating stabilization [2][3][11]. Asset Quality - The non-performing loan ratio at the end of the first half of 2024 was 1.08%, showing a slight increase of 1 basis point from the end of the first quarter. The company also reported a rise in the restructured loan ratio and a decrease in the provision coverage ratio [3][11][19]. Growth and Expansion - The company’s total assets grew by 4.6% year-on-year, with risk-weighted assets increasing by 5.5%. The internal capital growth rate was reported at 7.7%, which is higher than the growth rate of risk-weighted assets, indicating a robust capital position [2][3][11]. Profitability Forecast - The report forecasts a net profit growth of 3.87% and 3.86% for the years 2024 and 2025 respectively, with expected earnings per share of 3.65 and 3.80 yuan per share. The current stock price corresponds to a price-to-earnings ratio of 4.60X and 4.42X for 2024 and 2025 respectively [2][3][11].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 74.90 CNY per share, corresponding to a 24-year PE of 25X [1][2] Core Views - The company's performance met expectations, with both domestic and international markets contributing to growth [1] - Revenue for the first half of 2024 reached 1.334 billion CNY, a YoY increase of 16.28%, driven by increased product sales in overseas markets [1] - Domestic market revenue was approximately 706 million CNY (YoY +1.73%), while international market revenue reached 624 million CNY (YoY +39.72%) [1] - Net profit attributable to the parent company was 310 million CNY, a YoY increase of 17.47%, with a gross margin of 67.94% (YoY +4.2pp) [1] - The company's overall expense ratio has been optimized, with sales expenses at 22.73% (YoY +0.68pp), management expenses at 12.43% (YoY -0.85pp), and R&D expenses at 5.22% (YoY -0.77pp) [1] Overseas Expansion and Cost Efficiency - The company has made significant progress in overseas construction, including the establishment of a European regional headquarters and the acquisition of channel companies in Portugal and Switzerland [1] - The US subsidiary has strengthened its local sales team, leading to a significant improvement in profits [1] - The company has set up an Australian office and is progressing with the construction of a production base in Thailand, expected to be operational by 2026 [1] - Operational improvements focus on "lean management efficiency, resource integration optimization, and process innovation cost reduction" to achieve sustainable profit growth [1] Financial Projections - EPS for 2024-2026 is projected to be 3.04 CNY/share, 3.83 CNY/share, and 4.89 CNY/share, respectively [1] - Revenue growth is expected to be 19.2% in 2024, 22.9% in 2025, and 23.7% in 2026 [3] - Net profit attributable to the parent company is forecasted to grow by 17.6% in 2024, 25.8% in 2025, and 27.7% in 2026 [3] Industry and Market Position - The company is a leader in the digestive endoscopy consumables sector, with a solid foundation in existing products and significant potential in the development of visualization products [1] - The recent easing of medical device centralized procurement policies has alleviated previous valuation pressures [1]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 12.21 CNY per share, compared to the current price of 8.74 CNY [5]. Core Insights - The company reported a revenue of 2.555 billion CNY for the first half of 2024, representing a year-on-year growth of 29.28%. The net profit attributable to shareholders was 809 million CNY, up 11.72% year-on-year, while the net profit excluding non-recurring items was 801 million CNY, an increase of 18.55% [3][4]. - The company has a rich reserve of IP resources and game products, with upcoming titles expected to contribute to revenue growth. Notable upcoming games include "Douluo Dalu: Zhu Xie Chuan Shuo" and "About My Reincarnation as a Slime: New World" [3]. - The company is actively expanding its overseas market, achieving significant growth in overseas revenue, which reached 126 million CNY in the first half of 2024, a year-on-year increase of 334.95% [3]. Financial Summary - Revenue projections for 2024-2026 are 5.396 billion CNY, 6.478 billion CNY, and 7.334 billion CNY, with year-on-year growth rates of 25.6%, 20.1%, and 13.2% respectively [4]. - The net profit attributable to shareholders is expected to be 1.753 billion CNY, 2.224 billion CNY, and 2.538 billion CNY for 2024-2026, with growth rates of 19.9%, 26.9%, and 14.1% respectively [3][4].